Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales

Source: Streetwise Reports   08/18/2021

Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.’s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a “Buy” rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential.

Dawson James Securities Inc.’s Senior Healthcare Analyst Jason Kolbert wrote in an August 17 research note that Fortress Biotech Inc.’s (FBIO:NASDAQ) commercially marketed dermatology products aided in delivering a positive revenue surprise in Q2/21.

The report indicated that during Q2/21, Fortress Biotech reported product revenues of $15 million, compared to $11.5 million in Q1/21. Dawson James commented that the Q2/21 revenue totals beat its estimates of $14 million and added that the company’s new dermatology products are highly complementary to its business and offer potential for further growth.

The analyst stated that “Fortress announced encouraging MB-107 and MB-207 clinical updates from its investigator-IND X-linked severe combined immunodeficiency (XSCID) trials.” The company is partnering with Mustang Bio Inc. (NASDAQ: MBIO) to develop and evaluate the safety and efficacy of these candidates in its investigator-IND X-linked severe combined immunodeficiency (XSCID) clinical studies.

Analyst Kolbert explained that in January 2021, “the FDA removed a CMC hold on the MB-107 Phase 2 clinical trial Investigational New Drug application after reviewing a comprehensive CMC package.” Kolbert noted that with the hold removed, Fortress now plans to enroll the first patient in this multicenter trial in Q3/21 and expects to receive the first top-line data in early 2022. In addition, Kolbert mentioned that Fortress expects to file an IND in H2/21 for a pivotal Phase 2 trial of MB-207.

The report listed that the company is also partnering with Mustang in a Phase 1/2 study of MB-106, which was described as “a CD20-targeted CAR T for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL).”

Another candidate in the Fortress pipeline is an anti-PD-L1 antibody called cosibelimab. The firm is partnering with Checkpoint Therapeutics (CKPT:OTC) and is evaluating the potential use for cosibelimab in treatment of metastatic cutaneous squamous cell carcinoma.

Other candidates in Fortress’s drug pipeline include olafertinib, “a light chain fibril-reactive monoclonal antibody for AL Amyloidosis,” CUTX-101, copper histidinate for Menkes disease, and dotinurad which is a urate transporter (URAT1) inhibitor for treating gout and perhaps other hyperuricemic indications including heart failure and chronic kidney disease.

Dawson James advised that it has a “Buy” rating for Fortress Biotech with a 12-month price target of $24.00. The company’s shares trade on the NASDAQ Exchange under the symbol FBIO and opened for trading on August 18, 2021 at $3.06/share.

Disclosures:

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.